Indicated for: breast cancer
Route of administration: injectable
Substance: eribulin (antineoplastic agent)
ATC: L01XX41 (Antineoplastic and immunomodulating agents | Other antineoplastic agents)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Eribulin is a chemotherapy medication used in the treatment of certain types of cancer, especially advanced breast cancer or liposarcoma. It works by inhibiting cell division, which stops the growth and multiplication of cancer cells.
Eribulin is administered by intravenous infusion at intervals determined by the oncologist, usually once every few weeks. The dose and frequency of treatment are tailored to each patient, depending on the response to therapy and any associated conditions.
Side effects may include fatigue, nausea, vomiting, decreased blood cell counts, hair loss, or, rarely, severe allergic reactions. Medical monitoring is essential throughout the treatment to manage possible complications.
Eribulin is an important option for patients with advanced cancer, offering the chance to slow disease progression and improve quality of life.